How does retatrutide differ from tirzepatide?

Tirzepatide is a GIP/GLP-1 dual agonist. Retatrutide adds glucagon receptor (GCGR) agonism as a third target. The GCGR activation drives hepatic fat oxidation and thermogenesis; co-administered GLP-1R agonism suppresses the hyperglycaemic effect of glucagon, producing net metabolic benefit without hyperglycaemia.

Is retatrutide available as a research chemical?

Some vendors sell a peptide labelled retatrutide under RUO framing. As an investigational drug with proprietary manufacturing details, sequence fidelity of vendor-sold material cannot be verified against a published standard. Standard RUO caveats — HPLC purity, mass-spec identity — apply with extra caution here.

GIP/GLP-1/Glucagon triple agonist · Investigational (Phase III)

Retatrutide: triple receptor agonism, ~24% Phase II weight loss, and what the TRIUMPH programme is testing.

By PeptideRadar Research Desk · April 18, 2026

INNRetatrutide (LY3437943) DeveloperEli Lilly TargetsGIP-R + GLP-1R + GCGR StatusPhase III (TRIUMPH) — not approved Updated2026-04-18

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). In a Phase II trial published in NEJM in 2023 (PMID 37358284), the 12 mg dose produced a mean weight loss of approximately 24% at 48 weeks — numerically ahead of both semaglutide's STEP-1 result (~15%) and tirzepatide's SURMOUNT-1 result (~22.5%), though these are separate trials in different populations. Phase III TRIUMPH trials are ongoing as of April 2026. Retatrutide is not FDA-approved.

Key points

Not approved. Retatrutide is investigational. No regulatory approval in any market as of April 2026. Phase III (TRIUMPH programme, Eli Lilly) ongoing.
Phase II (Jastreboff et al., NEJM 2023, PMID 37358284): 338 participants with obesity (no T2DM); 48 weeks. Retatrutide 12 mg: mean −24.2% body weight vs −2.1% placebo. 92% achieved ≥5% weight loss; 26% achieved ≥30%.
Triple receptor targeting: GIP-R + GLP-1R (same as tirzepatide) + GCGR (glucagon receptor). The GCGR addition is the novel element relative to tirzepatide.
Glucagon receptor agonism raises important questions about liver fat reduction (hepatic glucagon signalling drives glycogenolysis and fat oxidation) and the hyperglycaemia risk that glucagon canonically produces — titered carefully alongside GLP-1R suppression of glucagon secretion.
Phase II PK/PD study (Heise et al., Lancet Diabetes Endocrinol 2023) characterised the dose-escalation safety profile and pharmacokinetics supporting once-weekly dosing.
As an unapproved investigational drug, retatrutide is not legitimately available as a pharmaceutical product. Research-chemical vendors selling "retatrutide" are selling a peptide of unverified sequence and purity under RUO framing; buyers should apply the same COA scrutiny as any RUO GLP-1 analog.

Why a triple agonist? The glucagon receptor rationale

The GLP-1/GIP dual agonism in tirzepatide already outperforms pure GLP-1 agonism. Adding a third receptor — the glucagon receptor (GCGR) — is pharmacologically counterintuitive at first: glucagon is classically a hyperglycaemic hormone that opposes insulin. Why would an anti-obesity drug target the receptor for a hormone that raises blood sugar?

The answer lies in glucagon's hepatic and metabolic effects beyond glycaemia. GCGR agonism in the liver drives fatty-acid oxidation, thermogenesis, and glycogenolysis. In the context of co-administered GLP-1R agonism — which suppresses pancreatic glucagon secretion and maintains insulin secretion — the systemic hyperglycaemic effect of glucagon is blunted. What remains is the hepatic fat-burning signal and the energy-expenditure effect. In rodent models, GCGR agonism combined with GLP-1R agonism produced larger fat mass reduction than either alone, without the glycaemic risk of glucagon given in isolation.

The clinical implementation required careful dose-finding: enough GCGR agonism for metabolic benefit, not so much that it overwhelmed the GLP-1R-mediated glucagon suppression and caused hyperglycaemia. Retatrutide is designed as a balanced triple agonist with tuned potency at each receptor — not an equal mix of three receptor interactions but a weighted ratio established in preclinical work to maximise weight loss while minimising glycaemic risk.

Triple vs dual: the mechanistic logic Tirzepatide adds GIP-R agonism to GLP-1R. Retatrutide adds GCGR agonism to both. The additional effect from the glucagon receptor appears to act primarily on energy expenditure and hepatic fat oxidation rather than on satiety or gastric motility — which means the mechanisms are genuinely additive rather than redundant, at least in the preclinical model. Whether this translates to larger clinical weight loss without proportionally larger risk is what the Phase III programme is designed to establish.

Phase II trial: Jastreboff et al., NEJM 2023 (PMID 37358284)

The primary Phase II publication (Jastreboff AM, et al. N. Engl. J. Med. 2023;389:514–526; PMID 37358284) enrolled 338 adults with obesity or overweight without type 2 diabetes. This was a 48-week, dose-ranging, randomised, double-blind, placebo-controlled trial testing five doses of retatrutide (1, 4, 8, and 12 mg once weekly) against placebo, with lifestyle counselling as background. Key results:

Dose	Mean weight change	≥5% weight loss	≥20% weight loss
Placebo	−2.1%	25%	2%
1 mg	−8.7%	73%	5%
4 mg	−17.3%	91%	36%
8 mg	−22.8%	100%	63%
12 mg	−24.2%	92%	72%

The 12 mg headline figure (−24.2%) is the number most cited in media coverage, and it is striking: 72% of participants at 12 mg lost more than 20% of body weight, and 26% (across the highest-dose cohort) lost more than 30%. These are Phase II figures from a dose-finding trial — typically powered for safety and dose selection, not the definitive efficacy estimate — and must be interpreted with that in mind.

Critical methodological context: Phase II trials are smaller than Phase III (338 participants vs SURMOUNT-1's 2,539) and are optimised for dose selection. The effect sizes in Phase II trials frequently shrink in larger Phase III replication — regression to the mean, regression dilution, and selection of healthier trial populations all play a role. The ~24% figure is the upper bound of the Phase II finding, not a confirmed Phase III result. Cross-trial comparisons with STEP-1 and SURMOUNT-1 should treat the retatrutide number with appropriate caution.

The trial also reported data in a T2DM sub-group (reported in the same NEJM paper), where retatrutide at 12 mg produced mean weight loss of ~16.9% at 24 weeks with substantial HbA1c reduction — broadly consistent with expectations for a dual/triple agonist in T2DM.

Pharmacokinetics: Heise et al., Lancet Diabetes Endocrinology 2023

A separate dose-escalation PK/PD study (Heise et al., Lancet Diabetes Endocrinol. 2023) characterised retatrutide's pharmacokinetics. Key findings:

Half-life: approximately 6 days, consistent with once-weekly subcutaneous dosing.
The half-life is longer than tirzepatide (~5 days) and significantly longer than semaglutide (~165 hours / ~7 days — actually similar). The clinical relevance of the half-life difference between retatrutide and semaglutide is minor; both support weekly dosing.
Steady-state pharmacokinetics were achieved by week 4–5, similar to other once-weekly GLP-1-class agents.
The fatty-acid modification (C20 fatty diacid) on retatrutide confers albumin binding and protease resistance, using the same general strategy as semaglutide and tirzepatide.

The Heise study provided the dose-escalation data used to design the Phase II protocol and to select the 4, 8, and 12 mg dose levels for the efficacy cohorts. It is the technical underpinning for the Phase III dose selection.

Safety signals from Phase II

The Phase II safety profile was broadly GLP-1-class consistent, with some triple-agonism-specific signals to track.

GI adverse events: Nausea, vomiting, and diarrhoea were the most common. Rates were dose-dependent and highest during dose escalation. Comparable to or marginally higher than semaglutide and tirzepatide at equivalent weight-loss doses — consistent with a more potent compound requiring more careful titration.
Heart rate: Modest mean increase of ~1–2 bpm, consistent with the GLP-1 class. The GCGR component may contribute additionally: glucagon classically has positive chronotropic effects, though the balanced receptor agonism is designed to minimise this.
Fasting glucose: No clinically significant hyperglycaemia in non-T2DM participants, despite GCGR agonism. This is the key pharmacological test of whether the GLP-1R-mediated glucagon suppression adequately counterbalances GCGR-driven glucose elevation — and Phase II suggests it does at these doses.
Liver enzymes: Some early signals of transaminase elevation were noted; hepatic effects (expected given GCGR's hepatic mechanism) are a specific monitoring priority in Phase III.
Thyroid: Same class-level boxed warning as GLP-1R agonists for thyroid C-cell tumours in rodents. Not a demonstrated human risk; contraindicated in MEN-2 and medullary thyroid carcinoma history.

Phase III: the TRIUMPH programme

Eli Lilly has advanced retatrutide into Phase III under the TRIUMPH programme name. As of April 2026, multiple TRIUMPH trials are registered (ClinicalTrials.gov) covering:

Obesity without T2DM (TRIUMPH-1 and equivalents) — the pivotal approval-enabling trial, mirroring SURMOUNT-1's design with longer duration and larger N.
T2DM + obesity (parallel to SURMOUNT-2 for tirzepatide).
Cardiovascular outcomes — an outcomes trial powered for MACE, the equivalent of SELECT for semaglutide and SURPASS-CVOT for tirzepatide.

Phase III results have not been published as of April 2026. Regulatory submission timing depends on Phase III completion; FDA approval for obesity is not expected before late 2026 at the earliest, and likely later if the cardiovascular outcomes trial is required for approval.

Not for human use — regulatory status is clear Retatrutide is an investigational drug in Phase III clinical trials. It is not FDA-approved, not EMA-approved, and not available as a legitimate pharmaceutical product outside of clinical trials. Research-chemical vendors selling "retatrutide" are selling a peptide of unverified sequence, purity, and biological activity under an RUO framing. The Phase II data is promising, but this is precisely the stage at which compounds sometimes fail in Phase III. Do not treat Phase II results as if they establish efficacy equivalent to a Phase III trial.

Positioning relative to semaglutide and tirzepatide

The logical question for anyone following this literature is whether retatrutide will displace tirzepatide the way tirzepatide displaced semaglutide as the weight-loss benchmark. The Phase II data is consistent with this possibility — but four caveats apply:

Phase II vs Phase III attrition. Phase II to Phase III effect size reduction is common. The ~24% Phase II result may shrink in the larger, more diverse Phase III population.
Safety complexity. Adding the glucagon receptor adds a safety monitoring burden — particularly for liver enzyme elevation and glucose homeostasis in T2DM patients. Phase III may reveal safety signals that constrain the dose ceiling.
CV outcomes data lag. Tirzepatide has SURPASS-CVOT (non-inferiority data); semaglutide has SELECT (superiority vs placebo). Retatrutide's cardiovascular outcomes trial results are years away. For physicians managing high-CV-risk patients, semaglutide's SELECT data may keep it preferred even if retatrutide produces more weight loss.
Market access and cost. A new product entering after tirzepatide will face entrenched market positions, payer contracts, and patient familiarity. Clinical superiority in weight loss doesn't automatically translate to faster uptake.

For the current evidence-based comparison of what's approved, the semaglutide vs tirzepatide comparison is the relevant spoke. The retatrutide vs tirzepatide spoke will address the pipeline comparison as Phase III data become available.

Where to read further

Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with obesity." N. Engl. J. Med. 2023;389:514–526. PMID 37358284.
Heise T, et al. "Dose-escalation, safety, tolerability, pharmacokinetics and pharmacodynamics of retatrutide (LY3437943), a novel GIP, GLP-1 and glucagon receptor agonist in patients with type 2 diabetes." Lancet Diabetes Endocrinol. 2023.
Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N. Engl. J. Med. 2022;387:205–216. PMID 35658024. (For cross-trial comparison.)
Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N. Engl. J. Med. 2021;384:989–1002. PMID 33567185. (For cross-trial comparison.)
Eli Lilly and Company. ClinicalTrials.gov: TRIUMPH programme (NCT identifiers for Phases III obesity and T2DM trials).

Frequently asked

Is retatrutide approved?

No. Retatrutide (LY3437943, Eli Lilly) is an investigational drug in Phase III clinical trials (the TRIUMPH programme) as of April 2026. It is not FDA-approved or approved by any regulatory authority. FDA approval for obesity is not expected before late 2026 at the earliest.

How does retatrutide produce more weight loss than tirzepatide?

Retatrutide adds glucagon receptor (GCGR) agonism to the GIP/GLP-1 dual agonism of tirzepatide. Glucagon receptor activation in the liver drives fatty-acid oxidation and energy expenditure. In the presence of GLP-1R agonism — which suppresses pancreatic glucagon and blunts the hyperglycaemic effect — the net result is enhanced metabolic fat burning without the hyperglycaemia that glucagon produces in isolation. This appears to produce additive weight loss beyond the dual-agonist mechanism.

What is the Phase II weight loss result?

In the Phase II trial (Jastreboff et al., NEJM 2023, PMID 37358284), the 12 mg dose of retatrutide produced a mean weight loss of approximately 24.2% at 48 weeks in adults with obesity without type 2 diabetes. 72% achieved ≥20% weight loss. These are Phase II figures from a dose-finding trial with 338 participants — larger Phase III trials are ongoing and may produce different effect sizes.

Can you get retatrutide as a research chemical?

Some research-chemical vendors sell a peptide labelled as "retatrutide" under RUO framing. As an investigational drug whose complete sequence, post-translational modifications, and manufacturing process are proprietary, the authenticity and sequence fidelity of any vendor-sold "retatrutide" cannot be verified against a published standard. Unlike semaglutide (which has a USP monograph) or tirzepatide (where the sequence is fully published), the analytical verification of RUO retatrutide is particularly difficult. The usual RUO caveats — HPLC purity, mass-spec identity — apply with extra weight here.

When will retatrutide be approved?

Phase III TRIUMPH trials are ongoing as of April 2026. Regulatory submission to FDA depends on Phase III completion; approval is not expected before late 2026 and may be later if cardiovascular outcomes data is required. Phase III results have not been published; all current efficacy data is from Phase II.

Reviewer sign-off Reviewed 2026-04-18 by the PeptideRadar Research Desk. Phase II figures cross-checked against Jastreboff NEJM 2023 (PMID 37358284) and Heise Lancet Diabetes Endocrinol 2023. Cross-trial figures cross-checked against Jastreboff NEJM 2022 (SURMOUNT-1, PMID 35658024) and Wilding NEJM 2021 (STEP-1, PMID 33567185). Regulatory status current as of 2026-04-18. Corrections: corrections@peptideradar.net.